AstraZeneca Adds Lung-Drug Offerings With Almirall Deal

AstraZeneca Plc (AZN), the U.K. drugmaker that resisted a Pfizer Inc. takeover attempt, is building up its respiratory business by buying the rights to Almirall SA’s (ALM) lung medicines for $875 million.

AstraZeneca will pay as much as $1.22 billion more if the drugs meet development and sales goals, the London-based company said in a statement today. Almirall, based in Barcelona, also will transfer its Sofotec inhalation device unit to AstraZeneca.

The deal adds to the $3.5 billion-a-year Symbicort treatment and gives AstraZeneca new versions of the medicines for chronic lung disease it acquired from Pearl Therapeutics last year. Because AstraZeneca already has a strong presence in respiratory medicine, today’s deal won’t have much impact on the company or its share price, said Mark Clark, an analyst at Deutsche Bank AG in London.

“It’s an OK deal, but it’s not the one to cause people to fundamentally reassess Astra, particularly vis a vis their continuing independence” from Pfizer, Clark said.

The deal will have no effect on AstraZeneca’s earnings next year and will add to them in 2016, AstraZeneca said.

Shares Rise

Almirall rose 7.9 percent, the biggest gain in more than two years, to 11.60 euros in Madrid. The company has a market value of about 2 billion euros ($2.7 billion). Chairman Jorge Gallardo and First Vice Chairman Antonio Gallardo own about 67 percent of the stock via two holding companies. AstraZeneca climbed less than 1 percent to 4,357.50 pence.

Photographer: Stefano Buonamici/Bloomberg

An Eklira Genuair inhaler unit is seen at the Almirall SA pharmaceutical plant in Barcelona. Close

An Eklira Genuair inhaler unit is seen at the Almirall SA pharmaceutical plant in Barcelona.

Photographer: Stefano Buonamici/Bloomberg

An Eklira Genuair inhaler unit is seen at the Almirall SA pharmaceutical plant in Barcelona.

As part of the agreement, AstraZeneca will acquire Eklira, also called Tudorza Pressair, a treatment for smoking-related diseases such as bronchitis and emphysema, which recorded 84 million euros in sales in 2013 and made up 12 percent of Almirall’s revenue.

Another lung drug, Ebastel, had revenues of 76 million euros. Almirall’s respiratory drugs combined for 211 million euros in sales.

Almirall is applying for U.S. approval to market a combination of Eklira with formoterol, developed with New York-based partner Forest Laboratories Inc. Although the combination is approved in Europe, U.S. regulators asked for additional data. Actavis Plc bought Forest this month.

Glaxo Competition

The Eklira-formoterol combination of drugs could come on the market faster than a treatment AstraZeneca acquired last year from Pearl Therapeutics, and could compete with GlaxoSmithKline Plc’s Anoro and Novartis AG’s Ultibro, said Michael Shah and Sam Fazeli, analysts for Bloomberg Intelligence, in a research note.

Glaxo, AstraZeneca’s larger rival, last week cut its forecast for the year as revenue from its best-selling lung medicine Advair continued to fall. Efforts to introduce newer respiratory drugs Anoro and Breo have taken longer to bear fruit than the company anticipated.

AstraZeneca rejected Pfizer’s bid of $117 billion in May, saying the U.K. drugmaker’s pipeline of experimental drugs made it more valuable as a standalone company. In a June interview, Pascal Soriot, the chief executive officer, said AstraZeneca wouldn’t make big takeovers part of its defense strategy, although he said he would consider small to medium-sized acquisitions.

Rothschild was sole financial adviser to Almirall on the deal. Covington & Burling LLP provided legal advice to AstraZeneca while CMS Cameron McKenna LLP provided legal advice to Almirall.

For Related News and Information: Pfizer Weighs Next Move as $117 Billion AstraZeneca Bid Ends

To contact the reporter on this story: Oliver Staley in London at

To contact the editors responsible for this story: Phil Serafino at Kristen Hallam

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.